{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:54:59Z","timestamp":1792018499121,"version":"4.4.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,7,16]],"date-time":"2013-07-16T00:00:00Z","timestamp":1373932800000},"content-version":"vor","delay-in-days":654,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"name":"Shire Human Genetic Therapies, Inc."}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Immunological Methods"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.jim.2011.07.020","type":"journal-article","created":{"date-parts":[[2011,8,8]],"date-time":"2011-08-08T12:01:01Z","timestamp":1312804861000},"page":"45-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease"],"prefix":"10.1016","volume":"373","author":[{"given":"M\u00e1rcia","family":"S\u00e9llos-Moura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samad","family":"Barzegar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luying","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Oommen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Durant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan A.","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jim.2011.07.020_bb0005","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency \u2014 macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jim.2011.07.020_bb0010","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1542\/peds.100.6.e11","article-title":"Management of neutralizing antibody to Ceredase in a patient with type 3 Gaucher disease","volume":"100","author":"Brady","year":"1997","journal-title":"Pediatrics"},{"key":"10.1016\/j.jim.2011.07.020_bb0015","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/glycob\/cwp138","article-title":"Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages","volume":"20","author":"Brumshtein","year":"2010","journal-title":"Glycobiology"},{"key":"10.1016\/j.jim.2011.07.020_bb0020","author":"EMEA"},{"key":"10.1016\/j.jim.2011.07.020_bb0025","author":"FDA"},{"key":"10.1016\/j.jim.2011.07.020_bb0030","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2147\/TCRM.S6955","article-title":"Optimal therapy in Gaucher disease","volume":"6","author":"Goker-Alpan","year":"2010","journal-title":"Ther. Clin. Risk Manag."},{"key":"10.1016\/j.jim.2011.07.020_bb0035","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","article-title":"Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources","volume":"122","author":"Grabowski","year":"1995","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jim.2011.07.020_bb0040","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0731-7085(03)00156-0","article-title":"Development of an animal\u2013human antibody complex for use as a control in ELISA","volume":"32","author":"Gu","year":"2003","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jim.2011.07.020_bb0045","author":"ICH"},{"key":"10.1016\/j.jim.2011.07.020_bb0050","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1089\/adt.2007.089","article-title":"Detection of high- and low-affinity antibodies against a human monoclonal antibody using various technology platforms","volume":"5","author":"Liang","year":"2007","journal-title":"Assay Drug Dev. Technol."},{"key":"10.1016\/j.jim.2011.07.020_bb0055","author":"Meso Scale Discovery"},{"key":"10.1016\/j.jim.2011.07.020_bb0060","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1023\/A:1013062600566","article-title":"Workshop on bioanalytical methods validation for macromolecules: summary report","volume":"18","author":"Miller","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jim.2011.07.020_bb0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jim.2004.06.002","article-title":"Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products","volume":"289","author":"Mire-Sluis","year":"2004","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.jim.2011.07.020_bb0070","first-page":"81","article-title":"The immunogenicity of biopharmaceuticals. Lessons learned and consequences for protein drug development","volume":"112","author":"Patten","year":"2003","journal-title":"Dev. Biol. (Basel)"},{"key":"10.1016\/j.jim.2011.07.020_bb0075","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood.V90.1.43.43_43_48","article-title":"Enzyme therapy in Gaucher disease type 1: effect of neutralizing antibodies to acid beta-glucosidase","volume":"90","author":"Ponce","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.jim.2011.07.020_bb0080","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1182\/blood.V82.5.1402.1402","article-title":"Antibody response in patients with Gaucher disease after repeated infusion with macrophage-targeted glucocerebrosidase","volume":"82","author":"Richards","year":"1993","journal-title":"Blood"},{"key":"10.1016\/j.jim.2011.07.020_bb0085","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1182\/blood.V93.6.2081.406k07_2081_2088","article-title":"Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration","volume":"93","author":"Rosenberg","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.jim.2011.07.020_bb0090","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.tibtech.2004.06.003","article-title":"When biotech proteins go off-patent","volume":"22","author":"Schellekens","year":"2004","journal-title":"Trends Biotechnol."},{"key":"10.1016\/j.jim.2011.07.020_bb0095","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2006.09.003","article-title":"The long-term international safety experience of imiglucerase therapy for Gaucher disease","volume":"90","author":"Starzyk","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.jim.2011.07.020_bb0100","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/S1079-9796(03)00012-3","article-title":"Enzyme therapy of Gaucher disease: clinical and biochemical changes during production of and tolerization for neutralizing antibodies","volume":"30","author":"Zhao","year":"2003","journal-title":"Blood Cells Mol. Dis."}],"container-title":["Journal of Immunological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175911002043?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022175911002043?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T21:25:27Z","timestamp":1762205127000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022175911002043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":20,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0022175911002043"],"URL":"https:\/\/doi.org\/10.1016\/j.jim.2011.07.020","relation":{},"ISSN":["0022-1759"],"issn-type":[{"value":"0022-1759","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease","name":"articletitle","label":"Article Title"},{"value":"Journal of Immunological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jim.2011.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier B.V.","name":"copyright","label":"Copyright"}]}}